Encorafenib plus cetuximab beyond progression in combination with FOLFIRI in BRAF V600E mCRC progressing on EC: Results from the ECLYPse phase II trial

Arndt Vogel· @ArndtVogel · X·2026-10-24 20:56· 1 天前评分70

正文 · 机器翻译

Encorafenib联合cetuximab在FOLFIRI基础上用于EC治疗期间出现进展的BRAF V600E mCRC患者的超越进展治疗：ECLYPse II期试验结果
#ESMO26 #ESMOAmbassadors
👉 mPFS: 7.1
👉 mOS: NR
👉ORR 15%
🧐继续使用EC的信号令人关注，若有更多转化数据会更好
@myESMO @ASCO

56 浏览 · 0 赞 · 2 转发 · 0 回复

会议摘要

2071O按 Proffered paper: Melanoma and other skin tumours 对上

STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma

https://esmocongress.esmo.org

788RO按 Rapid oral: Gastrointestinal tumours, lower digestive 对上

Encorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial

https://esmocongress.esmo.org

NCT06578559NCT06578559按 - **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC 对上

- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

https://esmocongress.esmo.org

NCT06640166NCT06640166按 - **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. 对上

- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

https://esmocongress.esmo.org

来源：Arndt Vogel · x.com